Needham & Company LLC Reaffirms “Buy” Rating for Autolus Therapeutics (NASDAQ:AUTL)

Autolus Therapeutics (NASDAQ:AUTL)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $10.00 price objective on the stock. Needham & Company LLC’s price target would suggest a potential upside of 344.44% from the company’s current price.

A number of other research firms have also commented on AUTL. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Friday, November 15th. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Stock Performance

Shares of NASDAQ:AUTL traded down $0.11 on Monday, hitting $2.25. 228,993 shares of the company were exchanged, compared to its average volume of 1,028,816. Autolus Therapeutics has a one year low of $2.07 and a one year high of $7.37. The firm has a market capitalization of $598.71 million, a price-to-earnings ratio of -1.86 and a beta of 2.05. The company’s 50 day moving average price is $2.83 and its two-hundred day moving average price is $3.60.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the prior year, the company earned ($0.26) EPS. Research analysts predict that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Several large investors have recently made changes to their positions in the stock. ProShare Advisors LLC bought a new stake in shares of Autolus Therapeutics in the second quarter valued at about $43,000. Capstone Investment Advisors LLC bought a new stake in Autolus Therapeutics in the 3rd quarter valued at approximately $51,000. Daiwa Securities Group Inc. lifted its stake in Autolus Therapeutics by 2,659.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock valued at $55,000 after acquiring an additional 15,293 shares in the last quarter. Herbst Group LLC acquired a new position in Autolus Therapeutics during the 3rd quarter worth approximately $91,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Autolus Therapeutics by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock worth $139,000 after acquiring an additional 14,959 shares in the last quarter. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.